{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.5","upperLimit":"25.1","value":"12.6"},{"groupId":"OG001","lowerLimit":"10.4","upperLimit":"14.5","value":"11.4"},{"comment":"Median and upper confidence limit are not estimable due to small sample size","groupId":"OG002","lowerLimit":"2.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Progression-free survival is the time from registration to disease progression or death. Patients alive without disease progression were censored at the time of the last disease assessment.","dispersionType":"90% Confidence Interval","groups":[{"description":"Lenalidomide days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days. Phase I will determine the dose of lenalidomide to be used in Phase II.\n\nGroup A=30-60 CrCl (mL/min): Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.","id":"OG000","title":"Group A=30-60 CrCl (mL/Min)"},{"description":"Lenalidomide days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days. Phase I will determine the dose of lenalidomide to be used in Phase II.\n\nGroup B=CrCL\\<30 mL/min not on dialysis: Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.","id":"OG001","title":"Group B=CrCL<30 mL/Min Not on Dialysis"},{"description":"Lenalidomide days 1-21 and Dexamethasone 40 mg days 1, 8, 15 and 22 every 28 days. Phase I will determine the dose of lenalidomide to be used in Phase II.\n\nGroup C=CrCL\\<30 mL/min and on dialysis: Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.\n\nDialysis includes hemodialysis or peritoneal dialysis. When lenalidomide and/or dexamethasone treatment occurs on a dialysis day, lenalidomide and/or dexamethasone must be taken after dialysis.","id":"OG002","title":"Group C=CrCL<30 mL/Min and on Dialysis"}],"paramType":"MEDIAN","populationDescription":"Patients treated at the recommended phase II dose","reportingStatus":"POSTED","timeFrame":"56 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}